Enveric Biosciences (NASDAQ:ENVB) Posts Earnings Results

Enveric Biosciences (NASDAQ:ENVB) announced its quarterly earnings results on Friday. The company reported ($0.57) earnings per share for the quarter, Zacks reports.

Enveric Biosciences Stock Performance

Shares of ENVB stock traded down $0.01 during trading hours on Friday, reaching $1.51. The company had a trading volume of 17,393 shares, compared to its average volume of 32,344. Enveric Biosciences has a twelve month low of $1.17 and a twelve month high of $13.25. The company has a market capitalization of $6.79 million, a P/E ratio of -0.12 and a beta of 1.23. The stock’s fifty day simple moving average is $1.47 and its 200 day simple moving average is $1.89.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ENVB shares. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Thursday, October 15th. Wall Street Zen raised Enveric Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Enveric Biosciences presently has a consensus rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs. Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.